OncLive TV

Shilpa Gupta, MD, discusses the background of the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

Eric A. Singer, MD, discusses the safety of perioperative nivolumab and cabozantinib in patients with metastatic clear cell renal cell carcinoma.

Brian C. Grieb, MD, PhD, discusses historical barriers to targeting the MYC oncogene in patients with colorectal cancer and the rationale for an ongoing phase 1/2 clinical trial that may demonstrate an effective way to target MYC in CRC and other solid tumors. 

Susan Bal, MD, assistant professor, University of Alabama at Birmingham, discusses key efficacy and safety data from the phase 2 KarMMa trial in patients with relapsed/refractory multiple myeloma.

Alexander Putnam Cole, MD, discusses the rationale for investigating the magnitude of racial and ethnic disparities in prostate cancer–specific survival in patients undergoing surgery vs radiotherapy.

Devika Das, MD, MSHQS, discusses the use of neoadjuvant and adjuvant chemoimmunotherapy for patients with resectable non–small cell lung cancer, and emphasizes the importance of multidisciplinary collaboration when incorporating these regimens into treatment approaches.

Morie A. Gertz, MD, discusses the rationale for the phase 3 AFFIRM-AL trial in patients with amyloid light chain amyloidosis and elaborates on the challenges that may arise when enrolling patients to this trial.

Attaya Suvannasankha, MD, discusses addressing the incidence of cytokine release syndrome in a first-in-human phase 1/2 trial for patients with relaped/refractory multiple myeloma.

Alaa Muslimani, MD, discusses unanswered questions in the treatment of patients with metastatic colorectal cancer, highlighting how these unmet needs may be addressed through continued research.

Lida A. Mina, MD, discusses the evolution of the antibody-drug conjugates fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine in HER2-positive breast cancer.

William (Bill) Stokes, MD, discusses the use of radiation vs surgery for the treatment of patients with human papillomavirus–related oropharyngeal squamous cell carcinoma.

Che-Kai Tsao, MD, discusses the investigation of cabozantinib in combination with nivolumab and ipilimumab in patients with renal cell carcinoma.

Laura Goff, MD, discusses the investigation of adjuvant atezolizumab plus bevacizumab in hepatocellular carcinoma.

Brian Henick, MD, discusses the 3-year updated data from a phase 2 trial investigating treatment with neoadjuvant atezolizumab plus chemotherapy in patients with resectable non–small cell lung cancer.

Thomas M. Habermann, MD, discusses ongoing clinical trials in mantle cell lymphoma and marginal zone lymphoma.

John Mascarenhas, MD, discusses first-line treatment decisions for patients with myelofibrosis.

Mariana X. Byndloss, DVM, PhD, discusses the relationship between the gut microbiome and the risk of developing cancers such as colorectal cancer.

R. Wendel Naumann, MD, FACOG, FACS, discusses how the evolution of immunotherapy has changed the treatment landscape for patients with recurrent or metastatic cervical cancer.

Thomas M. Habermann, MD, discusses the data that led to the decision to withdraw the indication for ibrutinib for the treatment of patients with mantle cell lymphoma.

Maya Khalil, MD, discusses the future investigations of immunotherapy in non–small cell lung cancer.

Susan Bal, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Michael K. Gibson MD, PhD, discusses advancements in the identification of key biomarkers for patients with gastric or gastroesophageal junction adenocarcinoma, and the subsequent development of biomarker-driven therapeutics in this disease space.

Matthew Galsky, MD, discusses the importance of developing specific disease classifications within non–clear cell renal cell carcinomas.

Joshua Reuss, MD, discusses the background of LP-300 and the rationale for evaluating the agent in the phase 2 HARMONIC trial in a never-smoker population of patients with advanced lung adenocarcinoma.

Thomas M. Habermann, MD, discusses the withdrawal of United States indications for ibrutinib in patients with mantle cell lymphoma who have previously received at least 1 therapy and in those with marginal zone lymphoma who require systemic treatment and have received at least 1 prior anti–CD20-based therapy.

Christopher W. Ryan, MD, discusses the role of adjuvant therapy for patients with renal cell carcinoma.

Laura Goff, MD, discusses the key takeaways from results of the phase 3 SWOG 1815 trial in newly diagnosed patients with advanced biliary tract cancers.

Jeffery Zonder, MD, discusses the management of toxicities associated with bispecific antibodies in patients with multiple myeloma.